Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
0.3108
Nov 19 • 3:59 PM ET Dollar change-0.0093 Percentage change(-2.91%)
Aftermarket Close
0.3108
Aftermarket • 5:00 PM ET Dollar change0.0000 Percentage change(0.00%)
Index
-
Market Cap
12.46M
Enterprise Value
11.52M
Income
-7.00M
Sales
3.09M
Book/sh
-0.06
Cash/sh
0.15
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
5
IPO
Nov 05, 2004
P/E
-
Forward P/E
-
PEG
-
P/S
4.03
P/B
-
P/C
2.06
P/FCF
-
EV/EBITDA
-
EV/Sales
3.73
Quick Ratio
1.69
Current Ratio
1.69
Debt/Eq
-
LT Debt/Eq
-
Option/Short
Yes / Yes
EPS (ttm)
-0.19
EPS next Y
-0.12
EPS next Q
-0.04
EPS this Y
17.39%
EPS next Y
36.84%
EPS next 5Y
64.84%
EPS past 3/5Y
13.04% 7.84%
Sales past 3/5Y
1.79% 14.04%
EPS Y/Y TTM
19.43%
Sales Y/Y TTM
-7.64%
EPS Q/Q
38.22%
Sales Q/Q
-61.44%
Insider Own
23.02%
Insider Trans
-2.82%
Inst Own
18.90%
Inst Trans
-2.53%
ROA
-71.43%
ROE
-47256.03%
ROIC
-283.40%
Gross Margin
17.85%
Oper. Margin
-236.15%
Profit Margin
-226.87%
SMA20
-13.72%
SMA50
-22.37%
SMA200
-57.06%
Trades
Shs Outstand
40.09M
Shs Float
30.86M
52W High
1.60 -80.58%
52W Low
0.30 3.55%
Volatility
12.13% 10.28%
ATR (14)
0.04
RSI (14)
34.24
Beta
1.11
Rel Volume
1.00
Avg Volume
139.33K
Volume
139,744
Perf Week
-11.23%
Perf Month
-22.30%
Perf Quarter
-54.96%
Perf Half Y
-58.00%
Perf YTD
-66.94%
Perf Year
-66.52%
Perf 3Y
-81.82%
Perf 5Y
-91.95%
Perf 10Y
-81.16%
Prev Close
0.32
Price
0.31
Change %
-2.91%
Consensus
Strong Buy
Avg. Price Target
$3.50
Implied Upside
+1,026.1%
Analysts3incl. previous ratings
Rating Distribution2 Buy · 1 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Oct 23, 2025Resumed
HH.C. Wainwright
Buy$3+865.3%
Sep 08, 2025Initiated
CCraig Hallum
Buy
Jul 18, 2022Downgrade
DDawson James
Buy → Neutral
Dec 17, 2021Initiated
HH.C. Wainwright
Buy$7+2,152.3%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Francisco Trust under agreemen10% OwnerJul 23 '26Sale1.3054,76071,3033,282,888Jul 24 05:11 PM
Francisco Trust under agreemen10% OwnerJul 22 '26Sale1.3338,01650,4813,337,648Jul 24 05:11 PM
Francisco Trust under agreemen10% OwnerJul 24 '26Sale1.212,6163,1733,280,272Jul 24 05:11 PM
Francisco Trust under agreemenGreater than 10% holderJul 21 '26Proposed Sale1.48364,387539,296Jul 21 05:52 PM
Dyadic International, Inc. engages in developing a gene expression platform for producing commercial quantities of industrial enzymes and other proteins. It focuses on further improving and applying its proprietary C1 technology, which is used in the discovery, development, and manufacture of biologic medicines and vaccines. The company was founded by Mark A. Emalfarb in 1979 and is headquartered in Jupiter, FL.
FounderMr. Mark A. Emalfarb
President & COOMr. Joseph P. Hazelton
M.B.A.Ms. Ping Wang Rawson CPA
Secretary of the BoardMs. Ana Gomez Rodriguez